Company news

Rezolute, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

October 14, 2026

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

October 5, 2026

Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update

September 24, 2026

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

September 9, 2026

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

June 17, 2026

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

June 3, 2026

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

June 2, 2026

Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

May 12, 2026

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

May 1, 2026

Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting

April 21, 2026

Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

March 23, 2026

Rezolute to Participate in the Citizens Life Sciences Conference

March 3, 2026

Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

February 12, 2026

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 3, 2026

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

January 6, 2026

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

December 10, 2025

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 9, 2025

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

November 5, 2025

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

November 4, 2025

Rezolute to Participate in Upcoming Investor Conferences

October 14, 2025

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

September 16, 2025

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

September 1, 2025

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

August 19, 2025

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

July 21, 2025

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

July 8, 2025

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 27, 2025

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 12, 2025

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

May 4, 2025

Rezolute, Inc. Announces Closing of Underwritten Offering

April 24, 2025

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

April 22, 2025

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

April 22, 2025

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

March 25, 2025

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

February 11, 2025

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

February 3, 2025

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

January 30, 2025

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

January 6, 2025

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

December 4, 2024

FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

December 2, 2024

Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

November 6, 2024

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

September 18, 2024

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

September 8, 2024

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

August 4, 2024

Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

June 26, 2024

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

June 23, 2024

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

June 12, 2024

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

June 12, 2024

Rezolute to Participate in the Jefferies Global Healthcare Conference

May 29, 2024

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

May 20, 2024

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

May 14, 2024

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

April 22, 2024

Older news releases →

Decks

The 5 newest of 22 decks. Every deck is listed under its year.